Health
LoDoCo2: Added Steam for Colchicine as Secondary Prevention – Medscape
The benefits emerged early and continued to accrue through the trial, with no suggestion of attenuation during up to 5 years of treatment.
The anti-inflammatory drug colchicine picked up new support as secondary prevention in chronic coronary disease, cutting the risk of cardiovascular events by one third when added to standard prevention therapies in the double-blind LoDoCo2 study.
Across a median follow up of 29 months in more than 5000 patients, almost 1 in 10 patients assigned to placebo experienced the primary endpoint of cardiovascular (CV) death, myocardial infarction (MI), ischemic stroke, or ischemia-driven coronary revas…
-
General11 hours agoAustralian celebrity chef Peter Russell-Clarke dies aged 89
-
Noosa News20 hours agoRainbow Beach surfer’s untold 7/7 story
-
Noosa News11 hours agoWoman airlifted to Brisbane hospital after big cat mauling at south-east Queensland zoo near Toowoomba
-
Noosa News10 hours agoUnvaccinated horse dies from Hendra virus as Queensland records first case in three years